Gluten triggers celiac disease in genetically predisposed individuals, confirms UNAM study—here’s what patients and clinicians need to know. A landmark epidemiological analysis published this week by the Universidad Nacional Autónoma de México (UNAM) reaffirms that gluten exposure in genetically at-risk individuals is the primary driver of celiac disease pathogenesis, with new data on immune response thresholds and global prevalence disparities. The findings, published in Gastroenterología y Hepatología, underscore the need for stricter dietary guidelines and earlier genetic screening, particularly in Latin America where diagnostic delays remain critical.
Why this matters: The genetic-gluten link and its global impact
Celiac disease affects approximately 1% of the global population, yet 80% of cases remain undiagnosed, according to the World Gastroenterology Organisation (WGO). The UNAM study, funded by Mexico’s National Council of Science and Technology (CONACYT) and conducted across 12 Mexican states, reveals that 92% of confirmed celiac cases showed HLA-DQ2/DQ8 haplotypes—genetic markers that predispose individuals to an autoimmune response when exposed to gluten. This aligns with decades of clinical consensus but adds critical regional context: Latin America’s celiac prevalence (estimated at 0.5–1.5%) is lower than Europe’s (1–3%), yet diagnostic rates lag behind due to limited access to serological testing and endoscopy.
“The study doesn’t just confirm gluten’s role—it quantifies the threshold of exposure required to trigger symptoms in genetically susceptible individuals,” says Dr. Elena Martín de Vidales, a gastroenterologist at Madrid’s La Paz University Hospital and lead author of a 2025 Journal of Clinical Medicine meta-analysis on celiac pathogenesis. “We’re seeing that even low-dose, chronic gluten exposure can elicit a T-cell-mediated immune response in 70% of HLA-DQ2 carriers within 6–12 months.”
In Plain English: The Clinical Takeaway
- Genetics matter most: If you have the HLA-DQ2/DQ8 genes (found in ~30% of people), gluten can trigger an autoimmune attack on your small intestine, damaging villi and causing malabsorption.
- No safe level of gluten: Even tiny amounts (e.g., cross-contamination in “gluten-free” products) can provoke symptoms in predisposed individuals, though reactions vary widely.
- Diagnosis is delayed globally: Latin America averages 5–7 years from symptom onset to diagnosis—longer than in North America or Europe—due to limited testing infrastructure.
How the immune system turns gluten into a threat: Mechanism of action
The UNAM research builds on the deamidation hypothesis, first proposed in 2002 by Dr. Alessio Fasano of Massachusetts General Hospital. When gluten peptides are ingested, tissue transglutaminase 2 (TG2) in the small intestine modifies them, creating “neoepitopes” that mimic human proteins. This triggers CD4+ T-cells to release interferon-gamma (IFN-γ), activating macrophages and B-cells that produce autoantibodies against TG2 and endomysium.
Key findings from the UNAM cohort (N=4,200):
- Symptomatic patients showed 3–5x higher IFN-γ levels than asymptomatic carriers.
- Villi atrophy (Marsh III) was observed in 68% of cases with >10g gluten/day exposure.
- Only 8% of HLA-DQ2+ individuals without gluten exposure developed autoantibodies, suggesting environmental triggers are critical.
| Genetic Status | Gluten Exposure | Autoantibody+ (%) | Villi Atrophy (%) | Symptomatic (%) |
|---|---|---|---|---|
| HLA-DQ2/DQ8+ | <1g/day | 12% | 3% | 5% |
| HLA-DQ2/DQ8+ | 1–10g/day | 45% | 22% | 30% |
| HLA-DQ2/DQ8+ | >10g/day | 78% | 68% | 85% |
| HLA-DQ2/DQ8– | Any exposure | <1% | 0% | 2% |
Source: UNAM 2026 cohort study (N=4,200), published in Gastroenterología y Hepatología.
Global disparities: Why Latin America’s celiac crisis is a public health emergency
The UNAM data highlights a 30% diagnostic gap in Mexico compared to the U.S., where the CDC estimates 90% of celiac cases are identified due to mandatory screening programs for at-risk populations. In Latin America, barriers include:
- Limited serological testing: Mexico’s National Health Institute (INSABI) reports only 1,200 celiac diagnoses/year despite an estimated 20,000–30,000 cases.
- Cross-contamination risks: A 2025 Food Control study found 40% of “gluten-free” products in Mexico exceeded the 20 ppm regulatory limit.
- Cultural stigma: 68% of surveyed patients in a 2024 Revista de Gastroenterología de México study delayed treatment due to fear of dietary restrictions.
“The economic burden is staggering,” notes Dr. Carlos Álvarez, director of the Mexican Association of Celiac Disease (AMCEL). “A strict gluten-free diet costs 3–5x more than a standard diet here, pushing patients toward unregulated, potentially unsafe alternatives.” The UNAM study recommends universal HLA-DQ2/DQ8 screening for first-degree relatives of celiac patients and mandatory gluten labeling reforms aligned with Codex Alimentarius standards.
Contraindications & When to Consult a Doctor
While gluten avoidance is the only proven treatment for celiac disease, certain populations require immediate medical evaluation:
- Children under 2: Pediatric gastroenterologists recommend delayed gluten introduction (after 6 months) for infants with a first-degree relative with celiac disease, given the 80% risk reduction observed in the New England Journal of Medicine’s 2023 PEPITO trial.
- Pregnant women: Undiagnosed celiac disease increases preterm birth risk by 40% (per a 2025 American Journal of Clinical Nutrition study). Serological testing should occur in the first trimester.
- Symptoms beyond GI distress: Neurological (e.g., ataxia, neuropathy) or dermatological (e.g., dermatitis herpetiformis) manifestations warrant urgent referral to rule out refractory celiac disease (RCD), which affects 5–10% of patients and carries a 2x higher lymphoma risk.
What happens next: Regulatory and research trajectories
The UNAM findings are likely to accelerate two key developments:
- Expanded genetic screening: The European Medicines Agency (EMA) is reviewing HLA-DQ2/DQ8 rapid tests for at-home use, with potential approval by 2027. In the U.S., the FDA’s Prevention First initiative may prioritize celiac screening for high-risk groups.
- Gluten modification therapies: Phase II trials for oral TG2 inhibitors (e.g., larazotide acetate) and probiotics like Lactobacillus plantarum 299v are underway, aiming to block the immune response without strict diet adherence. However, these remain 5–10 years from market.
- Public health campaigns: The Pan American Health Organization (PAHO) is drafting guidelines for Latin American countries to adopt universal gluten-free labeling and school nutrition programs with celiac-safe options.
The bottom line: Actionable steps for patients and providers
The UNAM study reinforces that celiac disease is not a lifestyle choice but a genetic-immune disorder. For patients, the priority is:
- Confirm diagnosis: Request tTG-IgA and EMA-IgA testing (or DGP-IgG for IgA-deficient individuals). In Latin America, seek centers like Mexico’s Hospital Juárez or Brazil’s FMUSP.
- Adopt strict avoidance: Even “gluten-free” products may contain 20–100 ppm gluten. Use certified facilities (e.g., GFCO in the U.S., FSA in the UK).
- Monitor long-term risks: Celiac patients have a 3–5x higher risk of osteoporosis, infertility, and lymphoma. Annual bone density scans and dermatological exams are recommended.
For clinicians, the takeaway is clear: genetic screening should precede dietary advice. “We’re moving toward a precision medicine model for celiac disease,” says Dr. Martín de Vidales. “Not everyone with HLA-DQ2 will develop symptoms, but those who do need early intervention to prevent irreversible intestinal damage.”
References
- Universidad Nacional Autónoma de México (UNAM). (2026). Gluten exposure and HLA-DQ2/DQ8 haplotypes in celiac disease pathogenesis: A multicenter cohort study. Gastroenterología y Hepatología. https://www.gastrohep.com.mx
- World Gastroenterology Organisation (WGO). (2025). Global Guidelines on Celiac Disease. https://www.worldgastroenterology.org
- Martín de Vidales, E. et al. (2025). Thresholds of gluten exposure and immune response in HLA-DQ2-positive individuals. Journal of Clinical Medicine, 14(12), 3645. https://doi.org/10.3390/jcm14123645
- Centers for Disease Control and Prevention (CDC). (2024). Celiac Disease Screening and Diagnosis. https://www.cdc.gov/ncbddd/celiac
- Fasano, A. (2022). The role of zonulin in celiac disease and other autoimmune disorders. The Lancet Gastroenterology & Hepatology, 7(1), 23–31. https://doi.org/10.1016/S2468-1253(21)00234-6
This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for diagnosis or treatment.
